Valvular Heart Disease Emergencies: A Comprehensive Review Focusing on the Initial Approach in the Emergency Department. / Emergências Relacionadas à Doença Valvar Cardíaca: Uma Revisão Abrangente da Abordagem Inicial no Departamento de Emergência.

Valvular heart disease (VHD) is an increasing health problem worldwide. Patients with VHD may experience several cardiovascular-related emergencies. The management of these patients is a challenge in the emergency department, especially when the previous heart condition is unknown. Specific recommendations for the initial management are currently poor. This integrative review proposes an evidence-based three-step approach from bedside VHD suspicion to the initial treatment of the emergencies. The first step is the suspicion of underlying valvular condition based on signs and symptoms. The second step comprises the attempt to confirm the diagnosis and assessment of VHD severity with complementary tests. Finally, the third step addresses the diagnosis and treatment options for heart failure, atrial fibrillation, valvular thrombosis, acute rheumatic fever, and infective endocarditis. In addition, several images of complementary tests and summary tables are provided for physician support.

A doença valvar cardíaca é um problema de saúde crescente no mundo. Os pacientes com valvopatia podem apresentar diversas emergências cardiovasculares. O manejo desses pacientes é um desafio no departamento de emergência, principalmente quando a condição cardíaca prévia é desconhecida. Atualmente, recomendações específicas para o manejo inicial são limitadas. A presente revisão integrativa propõe uma abordagem baseada em evidência, de três etapas, desde a suspeita de valvopatia à beira do leito até o tratamento inicial das emergências. A primeira etapa é a suspeita de uma condição valvar subjacente com base nos sinais e sintomas. A segunda etapa consiste na tentativa de confirmação diagnóstica e avaliação da gravidade da valvopatia com exames complementares. Finalmente, a terceira etapa aborda as opções diagnósticas e terapêuticas para insuficiência cardíaca, fibrilação atrial, trombose valvar, febre reumática aguda, e endocardite infecciosa. Além disso, apresentamos imagens de exames complementares e tabelas para apoio aos médicos.

Managing acute cardiac valvular emergencies in the emergency department.

Valvular heart disease is becoming more prevalent as the United States' population ages, with aortic and mitral valves most commonly affected. Complications, including syncope, heart failure, dyspnea, and chest pain, can arise from slow progression of stenosis and regurgitation, though acute regurgitation from an ischemic or traumatic event can be life-threatening. Patients with valvular disease may present with cardiogenic shock, and vasoactive agent treatment will depend on determination of the valvular etiology. This issue reviews aortic and mitral valvular disease as potential causes of a patient's emergency department presentation, including history, diagnostic testing, and physical examination findings that can help guide treatment.

Heterogeneidad del tratamiento para cándida parapsilosis en endocarditis micótica de válvula nativa / Types of treatments for native-valve endocarditis due to candida parapsilosis

Introducción: las infecciones por cándida en el ámbito intrahospitalario han ido en ascenso en las últimas décadas en especial en las unidades de cuidado intensivo (UCI), dado el uso cada vez más frecuente de antibióticos de amplio espectro y de procedimientos invasivos tanto diagnósticos como terapéuticos. Hoy se consideran las especies de cándida como la cuarta causa de infección del torrente sanguíneo en los Estados Unidos de Norteamérica, con alto riesgo de complicaciones que incluyen endocarditis, trombosis y embolismo séptico al sistema nervioso central (SNC) entre otros. En relación con la endocarditis por especies de cándida, se ha considerado de mal pronóstico por el alto riesgo de afectación al SNC, por lo que se ha recomendado el manejo quirúrgico como piedra angular de su tratamiento. Presentación del caso: se describe el caso clínico de un paciente con endocarditis y con candidemia por Candida parapsilosis a quien se le realizó manejo médico.

Nosocomial Candida infections have increased in the last decades particularly in the intensive care units (ICU) due to the rise in broad-spectrum antibiotics usage and invasive diagnostic and therapeutic procedures usage. Today, Candida species are recognized as the fourth causative organisms of endovascular infection in the United States of America posing a high risk of endocarditis, thrombosis and septic embolization to the central nervous system (CNS). Endocarditis due to Candida species is associated with a poor prognosis because of the increased risk of CNS involvement for which surgical approach has been recommended as the cornerstone of therapy. We hereby report a patient with endocarditis and candidemia due to Candida parapsilosis, who received medical management.

Análise crítica dos estudos que mudaram a prática clínica recente: doença valvar / Critical analysis of studies that have changed recent clinical practice: valvular heart disease

Nesta breve análise crítica, discutiremos três estudos com potencial de alterar a prática clínica e as principais diretrizes internacionais no que tange à doença valvar. O estudo PARTNER III foi um estudo que randomizou 1000 pacientes de baixo risco cirúrgico entre troca valvar transcateter e cirurgia convencional, com superioridade da técnica transcateter em um desfecho primário combinado de mortalidade de todas as causas, acidente vascular cerebral (AVC) e re-hospitalização em doze meses de seguimento (8,5%vs.15,1%, p = 0,001). Já o estudo Evolut Low Risk randomizou 1468 pacientes entre as duas técnicas, com um desfecho primário de mortalidade ou AVC incapacitante ao final de dois anos de seguimento que atingiu não-inferioridade na comparação Bayesiana (5,3% transcateter vs . 6,7% cirurgia). Finalmente, discutimos também o estudo COAPT, no qual 614 pacientes foram randomizados entre o dispositivo edge-to-edge MitraClip e o tratamento clínico da insuficiência mitral secundária. Nesses pacientes selecionados, a taxa anualizada de hospitalizações por insuficiência cardíaca foi de 35,8% por paciente-ano no grupo MitraClip, comparado com 67,9% no grupo controle (HR 0,53, IC 95% 0,4-0,7).Nas novas diretrizes, pode-se razoavelmente esperar uma indicação I para a troca valvar transcateter em pacientes de baixo risco e uma indicação IIa para a técnica edge-to-edge em pacientes com características semelhantes aos do COAPT. Esses procedimentos devem ser considerados no contexto do Heart Team para que sejam atingidos os melhores resultados

In this short critical review, we will discuss three trials with the potential to alter clinical practice and the main international guidelines regarding valvular heart disease. The PARTNER III trial was a study of 1000 low surgical risk patients randomized between transcatheter aortic valve replacement (TAVR) and conventional surgery, showing the superiority of the transcatheter technique with a combined primary endpoint of all-cause mortality, stroke and rehospitalization over twelve months of follow-up (8.5%vs. 15.1%, p = 0.001). The Evolut Low Risk trial randomized 1468 patients between the two techniques with a primary endpoint of death or incapacitating stroke at the end of two years of follow-up, achieving non-inferiority in a Bayesian comparison (5.3% TAVR vs. 6.7% surgery). Finally, we also will discuss the COAPT study, in which 614 patients were randomized between the edge-to-edge MitraClip device and clinical treatment for secondary mitral regurgitation. Among these selected patients, the annual rate of hospitalizations for heart failure was 35.8% per patient-year in the MitraClip group, compared with 67.9% in the control group (HR 0.53, 95% CI 0.4-0.7). Under the new guidelines, we may reasonably expect a class I indication for transcatheter valvular replacement in low-risk patients and a class IIa indication for the edge-to-edge technique in patients with characteristics similar to those of the COAPT study. These procedures should be considered within the context of the Heart Team so that the best results are achieved

INCA (Peru) Study: Impact of Non-Invasive Cardiac Magnetic Resonance Assessment in the Developing World.

Background Advanced cardiac imaging permits optimal targeting of cardiac treatment but needs to be faster, cheaper, and easier for global delivery. We aimed to pilot rapid cardiac magnetic resonance ( CMR ) with contrast in a developing nation, embedding it within clinical care along with training and mentoring. Methods and Results A cross-sectional study of CMR delivery and clinical impact assessment performed 2016-2017 in an upper middle-income country. An International partnership (clinicians in Peru and collaborators from the United Kingdom, United States, Brazil, and Colombia) developed and tested a 15-minute CMR protocol in the United Kingdom, for cardiac volumes, function and scar, and delivered it with reporting combined with training, education and mentoring in 2 centers in the capital city, Lima, Peru, 100 patients referred by local doctors from 6 centers. Management changes related to the CMR were reviewed at 12 months. One-hundred scans were conducted in 98 patients with no complications. Final diagnoses were cardiomyopathy (hypertrophic, 26%; dilated, 22%; ischemic, 15%) and 12 other pathologies including tumors, congenital heart disease, iron overload, amyloidosis, genetic syndromes, vasculitis, thrombi, and valve disease. Scan cost was $150 USD, and the average scan duration was 18±7 minutes. Findings impacted management in 56% of patients, including previously unsuspected diagnoses in 19% and therapeutic management changes in 37%. Conclusions Advanced cardiac diagnostics, here CMR with contrast, is possible using existing infrastructure in the developing world in 18 minutes for $150, resulting in important changes in patient care.

The homing of bone marrow stem cells is differentially activated in ischemic and valvular heart diseases and influenced by beta-blockers.

BACKGROUND: Cell homing is the mechanism by which an injury releases signaling molecules that cause recruitment, proliferation, migration and differentiation of progenitor cells. Stromal derived factor-1 (SDF-1) and its receptor CXCR4 are key molecules involved in homing and little is known about their activation in cardiopathies. Here, we assessed the homing activation status of bone marrow cells (BMC) concerning the SDF-1 and CXCR4 expression in ischemic (IHD) and valvular (VHD) heart diseases. METHODS: The SDF-1 and inflammatory profile were analyzed by ELISA from plasma obtained bone marrow of ischemic heart patients (IHD, n = 41), valvular heart patients (VHD, n = 30) and healthy controls (C, n = 9). Flow cytometry was used to evaluate CXCR4 (CD184) expression on the surface of bone marrow cells, and the CXCR4 expression was estimated by real-time quantitative PCR. RESULTS: The SDF-1 levels in the groups IHD, VHD and control were, respectively, 230, 530 and 620 pg/mL (P = 0.483), and was decreased in VHD patients using beta-blockers (263 pg/mL) when compared with other (844 pg/mL) (P = 0.023). Compared with IHD, the VHD group showed higher CXCR4 (P = 0.071) and CXCR7 (P = 0.082) mRNA expression although no difference in the level of CXCR4+ bone marrow cells was found between groups (P = 0.360). CONCLUSION: In conclusion, pathophysiological differences between IHD and VHD can affect the molecules involved in the activation of homing. In addition, the use of beta-blockers appears to interfere in this mechanism, a fact that should be considered in protocols that use BMC.

Terapia anticoagulante nas valvopatias / Anticoagulant therapy in valvulopathies

As valvopatias, especialmente na presença da fibrilação atrial (FA), aumentam o risco de eventos tromboembólicos que, além de modificar a história natural da doença, têm impacto significativo na sobrevida e na qualidade de vida dos pacientes. Além do envelhecimento da população mundial, com o consequente número crescente de pacientes com fibrilação atrial, há cada vez mais associações de valvopatias com a doença arterial coronariana (DAC). Nesse grupo de pacientes para os quais há indicação emergencial ou eletiva de intervenção coronariana percutânea (ICP) com implante de stents, serão prescritos antiplaquetários e anticoagulantes ao menos nos primeiros meses pós-ICP. A prevenção do tromboembolismo (TE) com anticoagulantes, como a varfarina ou com os anticoagulantes orais diretos (AOD), é recomendada na maioria das diretrizes. O emprego dos escores CHADS2-VASc e HAS-BLED são úteis para a quantificação dos riscos TE e hemorrágicos

Valvulopathies, especially in the presence of atrial fibrillation (AF), increase the risk of thromboembolic events, which in addition to modifying the natural history of the disease; have a significant impact on survival and quality of life of patients. In addition to the aging of the world's population, with a consequent increase in the number of patients with atrial fibrillation, there are increasing cases of associations of valvular diseases with coronary artery disease (CAD). In this group of patients, in whom there is an emergency or elective indication for percutaneous coronary intervention (PCI) with the implantation of stents, antiplatelet and anticoagulant therapies will be prescribed, at least in the first months after PCI. The prevention of thromboembolic events (TE) with anticoagulants, such as warfarin, or with direct oral anticoagulants (DAOCs), is recommended in most of the Guidelines. The use of the CHADS2-VASc and HAS-BLED scores are useful in the quantification of TE and hemorrhagic risks

Exercise training of dogs with myxomatous valve disease / Treinamento físico de cães com doença mixomatosa valvar

The present study has the objective of evaluating the effects of exercise training, using moderate intensity walking (60 to 80% of maximum heart rate), from 30 to 50 minutes, three times a week, in alternate days, during eight weeks, on heart rate variability in dogs with myxomatous valve disease (MVD). For that, 20 dogs in stages B1 (1), B2 (14) and C2 (5) of MVD (ACVIM classification) were divided into untrained control group (CG, n=9) and training group (TG, n=11), and assessed at baseline (T0), after four (T1) and eight weeks (T2). Only one B1 and five B2 dogs completed the training program. In the time domain, the rMSSD was greater in TG in T1 (155,5+42,07) and T2 (199,8+83,54) than CG (T1:91,17+35,79 and T2:88,17+57,51). In the frequency domain, the variable High Frequency (HF) increased in TG in T1 (30950+25810) and T2 (40300+33870) when compared to the CG (T1:19090+23210 and T2:18810+22200) and within the group TG in T2 in relation to T0 (29340+20950). The proposed walking protocol is concluded to have increased the rMSSD and HF variables in TG, representing an increase of the parasympathetic tonus, justifying the indication of this therapy in B1 and B2 stages of MVD.(AU)

O presente estudo objetivou avaliar o efeito do treinamento físico, utilizando-se a caminhada de moderada intensidade (60 a 80% da frequência cardíaca máxima), por 30 a 50 minutos, três vezes por semana, em dias alternados, durante oito semanas, sobre a variabilidade da frequência cardíaca em cães com degeneração mixomatosa valvar (DMV). Para tanto, 20 cães nos estágios B1 (1), B2 (14) e C2 (5) da DMV (classificação ACVIM) foram divididos em grupo controle não treinado (GC, n=9) e grupo treinamento (GT, n=11) e avaliados no início do estudo (T0), após quatro (T1) e oito semanas (T2). Apenas um cão B1 e cinco B2 completaram o programa de treinamento. No domínio do tempo, a variável rMSSD foi maior no GT em T1 (155,5+42,07) e T2 (199,8+83,54) que o GC (T1:91,17+35,79 e T2:88,17+57,51). No domínio da frequência, a variável High Frequency (HF) aumentou no GT em T1 (30950+25810) e T2 (40300+33870) comparada à do GC (T1:19090+23210 e T2:18810+22200), e dentro do GT no T2 em relação ao T0 (29340+20950). Dessa forma, conclui-se que o protocolo de treinamento proposto aumentou as variáveis rMSSD e HF no GT, representando aumento do tônus parassimpático, o que fundamenta a indicação dessa terapia nos estágios B1 e B2 da DMV.(AU)

Exercise training of dogs with myxomatous valve disease / Treinamento físico de cães com doença mixomatosa valvar

The present study has the objective of evaluating the effects of exercise training, using moderate intensity walking (60 to 80% of maximum heart rate), from 30 to 50 minutes, three times a week, in alternate days, during eight weeks, on heart rate variability in dogs with myxomatous valve disease (MVD). For that, 20 dogs in stages B1 (1), B2 (14) and C2 (5) of MVD (ACVIM classification) were divided into untrained control group (CG, n=9) and training group (TG, n=11), and assessed at baseline (T0), after four (T1) and eight weeks (T2). Only one B1 and five B2 dogs completed the training program. In the time domain, the rMSSD was greater in TG in T1 (155,5+42,07) and T2 (199,8+83,54) than CG (T1:91,17+35,79 and T2:88,17+57,51). In the frequency domain, the variable High Frequency (HF) increased in TG in T1 (30950+25810) and T2 (40300+33870) when compared to the CG (T1:19090+23210 and T2:18810+22200) and within the group TG in T2 in relation to T0 (29340+20950). The proposed walking protocol is concluded to have increased the rMSSD and HF variables in TG, representing an increase of the parasympathetic tonus, justifying the indication of this therapy in B1 and B2 stages of MVD.(AU)

O presente estudo objetivou avaliar o efeito do treinamento físico, utilizando-se a caminhada de moderada intensidade (60 a 80% da frequência cardíaca máxima), por 30 a 50 minutos, três vezes por semana, em dias alternados, durante oito semanas, sobre a variabilidade da frequência cardíaca em cães com degeneração mixomatosa valvar (DMV). Para tanto, 20 cães nos estágios B1 (1), B2 (14) e C2 (5) da DMV (classificação ACVIM) foram divididos em grupo controle não treinado (GC, n=9) e grupo treinamento (GT, n=11) e avaliados no início do estudo (T0), após quatro (T1) e oito semanas (T2). Apenas um cão B1 e cinco B2 completaram o programa de treinamento. No domínio do tempo, a variável rMSSD foi maior no GT em T1 (155,5+42,07) e T2 (199,8+83,54) que o GC (T1:91,17+35,79 e T2:88,17+57,51). No domínio da frequência, a variável High Frequency (HF) aumentou no GT em T1 (30950+25810) e T2 (40300+33870) comparada à do GC (T1:19090+23210 e T2:18810+22200), e dentro do GT no T2 em relação ao T0 (29340+20950). Dessa forma, conclui-se que o protocolo de treinamento proposto aumentou as variáveis rMSSD e HF no GT, representando aumento do tônus parassimpático, o que fundamenta a indicação dessa terapia nos estágios B1 e B2 da DMV.(AU)

Tratamento percutâneo da insuficiência mitral por MitraClip®: relato dos dois primeiros procedimentos no Brasil / Percutaneous treatment of mitral regurgitation by MitraClipTM: report on the first two procedures in Brazil

O sistema MitraClip® foi recentemente aprovado para uso clínico no Brasil para o tratamento percutâneo da insuficiência valvar mitral. Esse dispositivo se baseia na cirurgia de Alfieri, criando um orifício duplo pela união central das duas cúspides da valva mitral. Descrevemos aqui os dois primeiros procedimentos realizados em nosso meio utilizando esse dispositivo. Tratam-se de duas pacientes do sexo feminino, consideradas de alto risco cirúrgico pela idade avançada e pela presença de comorbidades, portadoras de insuficiência mitral degenerativa por prolapso/flail associado à rotura de cordoalhas. Nos dois casos, obteve-se redução expressiva da intensidade da regurgitação mitral com a utilização do MitraClip®, demonstrando o grande potencial dessa tecnologia inovadora para o tratamento percutâneo da insuficiência valvar mitral.

The MitraClipTM system has been recently approved for clinical use in Brazil for percutaneous treatment of mitral valve regurgitation. This device is based on the Alfieri surgical procedure, creating a double orifice by bringing together the central segments of the two mitral valve cusps. This report describes the first two procedures performed in Brazil using this device. Two female patients considered to be at high surgical risk due to advanced age and presence of comorbidities were treated, with degenerative mitral regurgitation due to prolapse/flail, associated with chordae tendineae rupture. In both cases, significant mitral regurgitation intensity reduction was obtained using the MitraClipTM, demonstrating the great potential of this innovative technology for the percutaneous treatment of mitral valve regurgitation.

Uso de stents recobertos no tratamento da coarctação da aorta / Use of covered stents in the treatment of aortic coarctation

Introdução: A ampla variedade morfológica das coarctações da aorta (CoA) e algumas complicações derivadasdo implante de stents convencionais tornam desejáveis a utilizaçào de stents recobertos (SR). Descrevemos aexperiência com o uso de SR para tratar CoA em crianças e adultos. Métodos: Foram revisados, retrospectivamente, os registros dos pacientes nos quais foram utilizados os SR. Os procedimentos foram realizados segundo a técnica consagrada. Foram estudados casos em que os SRforam utilizados como primeiro tratamento e também aqueles realizados em complicações derivadas doprocedimento inicial. Resultados: Entre 2007 e 2014, foram utilizados SR em 14 pacientes, sendo 9 (64,3%) do sexo masculino. A média de idades foi 19,5 ± 10,5 anos, e a média dos pesos, 61,7 ± 25,5 kg. Valva aórtica bicúspide estavapresente em 74% dos casos, e dois apresentaram persistência do canal arterial. Coarctações subatréticasforam encontradas em cinco pacientes. Onze pacientes apresentaram hipertensão arterial sistêmica, e73% normalizaram as cifras tensionais após a dilatação com stents. O implante foi possível em todos os casos. Foram realizados implantes primários em dez (71,4%) pacientes portadores de coarctações nativas e em quatro como segundo dispositivo, para corrigir problemas derivados de procedimentos anteriores. O tempo médio de seguimento foi de 51,7 ± 29,8 meses. Três complicações menores estiveram relacionadas aos procedimentos, e não houve registro de óbito. Conclusões: O uso de SR foi seguro e eficaz na nossa pequena série de casos. Mais estudos, enfocando a evolução de longo prazo e a possibilidade de redilatação dos SR, são necessários para corroborar seu uso em crianças.

Background: The wide morphological variety of coarctation of the aorta (CoA) and some complications resulting from the implantation of conventional stents has made the utilization of covered stents (CS) desirable. We describe our experience with the use of CS to treat CoA in children and adults. Methods: The records of patients that received CS were retrospectively reviewed. The procedures were performed according to the established technique. Use of CS as primary treatment were assessed, as well as those deployed due to complications resulting from the initial procedure. Results: Between 2007 and 2014, CS were used in 14 patients, 9 (64.3%) of whom were males. The meanage was 19.5 ± 10.5 years, and the mean weight 61.7 ± 25.5 kg. Bicuspid aortic valve was present in 74% ofcases, and two patients had patent ductus arteriosus. Subatretic aortic coarctations were found in five patients. Eleven patients had systemic arterial hypertension, and 73% had normalized blood pressure levelsafter stent dilation. Implantation was possible in all cases. Primary implants were performed in ten (71.4%)patients with native coarctation and in four patients as a second device to correct problems originating from previous procedures. The mean time of follow-up was 51.7 ± 29.8 months. Three minor complicationswere related to procedures, and there were no deaths. Conclusions: The use of CS was safe and effective in this small case series. Further studies focusing on the long-term evolution and the possibility of CS redilation are needed to support its use in children.

Abordagem e tratamento da estenose aórtica assintomática / Evaluation and treatment of asymptomatic aortic stenosis

A estenose aórtica degenerativa representa atualmente a valvopatia mais frequente nos países desenvolvidos, com prevalência de 3% a 5% na população acima dos 75 anos de idade. Do ponto de vista epidemiológico, o Brasil apresenta distribuição bimodal da prevalência de estenose aórtica, aco- metendo idosos (etiologia calcifica/degenerativa) e faixas etárias mais jovens, devido, sobretudo, à febre reumática e alterações congênitas (valvas bicúspides). Clinicamente, a estenose aórtica caracteriza-se por sintomas de insufici- ência cardíaca esquerda associados à dor torácica anginosa e síncope. Atualmente, observamos um crescente interesse no manejo da estenose aórtica degenerativa sem sintomas. A análise do perfil dos portadores de estenose aórtica assin- tomáticos revela grande heterogeneidade clínica. Diversos estudos descrevem preditores de mau prognóstico para estes pacientes, os quais devem ser levados em conta na estratificação de risco e definição do momento ideal para a intervenção cirúrgica.

Degenerative aortic stenosis is currently the most common valvular heart disease in developed countries, with prevalence ranging from 3 to 5% in the population above 75 years of age. From an epiderniological perspective, Brazil has a classical bi- modal distribution of the prevalence of aortic stenosis, affecting both elderly (calcification/degenerative etiology) and younger age groups, especially due to rheumatic fever and congenital abnormalities (bicuspid valves). Clinically, aortic stenosis is characterized by symptoms of left heart failure associated with anginal chest pain and syncope. Currently, we could observe an increasing interest in the management of degenerative aor- tic stenosis without symptoms. The analysis of the profile of asymptomatic aortic stenosis shows great clinical heterogeneity. Several studies describe predictors of poor prognosis for these patients, which should be taken into account in risk stratification and definition of the optimal time for surgical intervention.

Importância dos métodos diagnósticos na estratificação da gravidade da estenose aórtica / Importance of diagnostic tests to evaluate the severity of aortic stenosis

A quantificação da gravidade da estenose aórtica é de fundamental importância na avaliação diagnóstica e prognóstica. É realizada mais frequentemente com os gradientes transvalvares, a velocidade máxima do fluxo através da valva e o cálculo da área valvar aórtica por meio da ecocardiografia Doppler. Outros métodos de imagem, como a tomografia computadorizada e ressonância magnética cardíaca, permitem obter informações complementares à ecocardiografia na avaliação da gravidade da doença. Nos últimos anos, com o melhor entendimento da doença, foram identificadas novas condições hemodinâmicas na estenose aórtica, como as situações de baixo fluxo transvalvar, com ou sem disfunção sistólica ventricular esquerda. Estes aspectos e a possibilidade de implante de prótese valvar por via percutânea trouxeram novas necessidades e desafios na avaliação diagnóstica de pacientes sintomáticos ou assintomáticos com estenose aórtica, os quais têm sido progressivamente superados com auxílio dos métodos de imagem.

The severity of aortic valve stenosis is fundamental for diagnosis and prognosis of the disease. This evaluation is most commonly performed by measuring transvalvar pressure gradients, peak aortic valve velocity and aortic valve area. Other cardiovascular imaging methods such as tomography and cardiac magnetic resonance al/ow additional information for evaluating the severity of the disease. In the last years with the improved knowledge of the disease, new hemodynamic conditions in aortic stenosis were identified, such as transval var low flow with or without left ventricular systolic dysfunction. The possibility of percutaneous prosthetic valve implantation is a challenge for new information in both symptomatic and asymptomatic patients.